A couple of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made huge purchases on Tuesday. Altogether, these funds bought over 850,000 shares of UiPath Inc. (NYSE: PATH) on Tuesday, as the price of these ETFs gained less than 1% on Tuesday. Note that these funds are still up handily in the last year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 291,229 shares of UiPath, and ARK Innovation ETF (NYSEARCA: ARKK) bought 566,900 shares. At Tuesday’s closing price, this would have valued these purchases at roughly $59.1 million. Even though this is a small fraction of the total holdings, every little bit counts. ARKG is up 84% in the past year and ARKK is up 92%.
Check out all of ARK Invest’s buys for Tuesday:
| Fund | Ticker | Company | Shares |
|---|---|---|---|
| ARKG | IONS | Ionis Pharmaceuticals | 268,748 |
| ARKG | PATH | UIPath | 291,229 |
| ARKK | PATH | UIPath | 566,900 |
| ARKQ | KTOS | Kratos Defense & Security Solutions | 50,625 |
| ARKQ | BZ | Kanzhun | 109,718 |
| ARKW | BZ | Kanzhun | 101,005 |
| ARKW | VUZI | Vuzix | 232,063 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
Retirement can be daunting, but it doesn’t need to be.
Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter!
Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality. (sponsor)
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
